Anilinoquinoline based inhibitors of trypanosomatid proliferation

Lori Ferrins, Amrita Sharma, Sarah M. Thomas, Naimee Mehta, Jessey Erath, Scott Tanghe, Susan E. Leed, Ana Rodriguez, Kojo Mensa-Wilmot, Richard J. Sciotti, Kirsten Gillingwater, Michael P. Pollastri

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

We recently reported the medicinal chemistry re-optimization of a series of compounds derived from the human tyrosine kinase inhibitor, lapatinib, for activity against Plasmodium falciparum. From this same library of compounds, we now report potent compounds against Trypanosoma brucei brucei (which causes human African trypanosomiasis), T. cruzi (the pathogen that causes Chagas disease), and Leishmania spp. (which cause leishmaniasis). In addition, sub-micromolar compounds were identified that inhibit proliferation of the parasites that cause African animal trypanosomiasis, T. congolense and T. vivax. We have found that this set of compounds display acceptable physicochemical properties and represent progress towards identification of lead compounds to combat several neglected tropical diseases.

Original languageEnglish
Article numbere0006834
JournalPLoS Neglected Tropical Diseases
Volume12
Issue number11
DOIs
StatePublished - Nov 2018
Externally publishedYes

Fingerprint

Dive into the research topics of 'Anilinoquinoline based inhibitors of trypanosomatid proliferation'. Together they form a unique fingerprint.

Cite this